Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. - Wikidata - wikimedia - TriplyDB

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.

http://www.wikidata.org/entity/Q37584869

about

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?--A pilot study.Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen Pathological complete response in younger and older breast cancer patients A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.Comparison of the diagnostic performance of response evaluation criteria in solid tumor 1.0 with response evaluation criteria in solid tumor 1.1 on MRI in advanced breast cancer response evaluation to neoadjuvant chemotherapy.Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer.Molecular basis for therapy resistance.Optimizing conservative breast surgery.18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study.Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer.Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis.Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma.

P2860

Q31150676-C386CB5B-06C0-40DC-B999-7623A3BC5C64 Q33685937-76881DBF-EEA5-40E1-B02D-63BD9C102E5E Q34331734-3BC3752A-C215-43B3-BD35-E3E3D8D90D22 Q34690824-32AF5A15-34ED-416D-9624-FE94763AA19A Q35023441-752787C3-C3CB-4E27-94DE-D7717DF24476 Q35036174-DAE2AD3A-F148-430B-AF66-DE12FD5EF7D0 Q35832458-288EC6A7-C507-4857-B563-F10B7E329171 Q35948773-7BCBF69D-E125-4B9A-96AE-D0E640E3271E Q35990463-73D46466-D71F-4546-9006-C950BF8014D2 Q36096451-07CA0264-0B74-4685-AA2C-D2A74F1A3D8D Q36326466-4B006C0E-D8B3-4706-853E-D9359615E597 Q36524335-6DA6C657-E748-4189-80F2-0C1A0EF03BD9 Q36866538-54B45F89-188E-407C-AFA5-9F007B882473 Q36868191-72A132B9-7C61-44D5-98E6-62DB5C12BB4B Q37038455-52C23792-7F8A-4088-8E1F-90580B657B6D Q37118205-A34E403D-A7C9-4746-9B4D-EAD8A311AE58 Q37220398-86EF4660-C72D-49DD-ACD7-E79E3E4BBD9B Q37575017-7AA8C58D-3AD6-4CD9-8315-9990B6C46547 Q37751530-E5FF987B-BFDC-4BA1-8A52-26B51D01C1FB Q37845308-B62BE08B-20CD-47D4-ABFD-B7B285182D15 Q38458792-1C0CD160-45BF-483D-8C9F-97EDAADEC193 Q38464311-EAAFD304-A247-4FA3-AFF0-082D3D224923 Q38696564-351EB824-0F7B-4776-A31C-9B7D49A93A63 Q39430849-722660D1-7D73-457A-A199-FAA354C7BF0A Q39685538-99D7B116-64E7-4BC3-8BA6-667C162A3B00 Q39932632-00EE1FD5-82A1-432F-B235-40A56AEC2C80 Q41483585-29096A17-D2E7-4480-BDAF-AFBB8DD71978 Q54395374-8BCDFA66-EEAB-4CFF-B2A6-BAA6DC3A6081 Q54525386-140E92C9-F5D4-4CDE-9AD7-07ECF4BBF841 Q54600159-A1A58319-8AE1-45A1-9328-8BB75EE14263

P2860

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.

http://www.wikidata.org/entity/Q37584869

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Predictors of complete patholo ...... mic therapy for breast cancer.

@en

Predictors of complete patholo ...... mic therapy for breast cancer.

@nl

type

label

Predictors of complete patholo ...... mic therapy for breast cancer.

@en

Predictors of complete patholo ...... mic therapy for breast cancer.

@nl

prefLabel

Predictors of complete patholo ...... mic therapy for breast cancer.

@en

Predictors of complete patholo ...... mic therapy for breast cancer.

@nl

P1433

Q37584869-4F9CF806-9B62-4996-B705-CC2CA20AF809

P1476

Q37584869-094A56A4-EC26-4590-A54A-9143B3CB6933

P2093

Q37584869-2A35A9CA-A80B-4890-86D9-5AF15F98E34A

Q37584869-2E97578D-3E34-492D-90F4-F960566B79E1

Q37584869-74D3C0BB-84DD-4EDF-A6B2-B93AD028F700

Q37584869-8941D2BC-5775-4AEA-842C-12E4819A82D0

Q37584869-90EE7D9D-B739-4402-8849-6AE752CB4A99

Q37584869-D70A7044-90BE-42B2-8C31-0C3C3F6F8DBD

P2860

Q37584869-033F0735-565F-459F-B742-677B66F5ECC7

Q37584869-0ADE7534-8DD2-4B5D-958E-C79921B8A970

Q37584869-10CD63BF-A761-4102-A55D-EB6EA8222031

Q37584869-157AA8FF-2B53-4E51-851E-679FF6E356B2

Q37584869-1AE80E16-F5D9-4669-B859-14835662E0AE

Q37584869-1F043A04-0C6A-47FA-948B-E766C47FDD38

Q37584869-2EAF93DE-D73F-4933-BA4C-568A525C8CC0

Q37584869-37CB889C-102F-4B44-9076-7D705068C2DB

Q37584869-41657A86-11E6-4B79-9952-D198D0D58878

Q37584869-52B82927-37FB-44C6-8EC7-994EB2C6E954

P304

Q37584869-3925D3E3-3522-4B28-842B-A8C1E5E7459B

P31

Q37584869-3ACB86B3-DE05-4FE9-AB37-0D554D2640A1

P356

Q37584869-D7790A96-F5DC-4023-A855-89F7DD3A1136

P407

Q37584869-E48762E3-E580-40F5-9597-EC7AC3F761DF

P433

Q37584869-D4EA6859-1036-476C-9EDE-83BC17E0BBB8

P478

Q37584869-6842F87B-0659-4D17-ACF6-5DE7C94EFA91

P50

Q37584869-CB18288D-9D40-4141-8DBC-93A9735C1514

P577

Q37584869-5395814C-7EDE-46E5-9D3B-C4CA347581DA

P698

Q37584869-5BCE8577-3F45-48FE-86FA-85042CD8BA4B

P932

Q37584869-8201ED9E-BFB2-458D-8B3D-C64132D94C92

P356

J.AMJSURG.2009.06.004

P1433

The American Journal of Surgery

P1476

Predictors of complete patholo ...... mic therapy for breast cancer.

@en

P2093

Fatema Al Mushawah

http://www.w3.org/2001/XMLSchema#string

Julie A Margenthaler

http://www.w3.org/2001/XMLSchema#string

Marcus C Tan

http://www.w3.org/2001/XMLSchema#string

Rebecca L Aft

http://www.w3.org/2001/XMLSchema#string

Timothy J Eberlein

http://www.w3.org/2001/XMLSchema#string

William E Gillanders

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular portraits of human breast tumours

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

Predictive markers of response to neoadjuvant chemotherapy in breast cancer.

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

P304

520-525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMJSURG.2009.06.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

198

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19800460

http://www.w3.org/2001/XMLSchema#string

P932

3924770

http://www.w3.org/2001/XMLSchema#string